FDA has granted IND approval for Immunic’s oral investigational drug IMU-838

Two phase 1 studies for IMU-838 in healthy volunteers have been completed

Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing

Series A financing round extended to EUR 21.7 Million